GSK Patent Suits Over Spikevax, mResvia Settled With No Payments Owed
MRNA has more than doubled off its 52-week low of $22.28.
Summary
GSK and Moderna settled the patent suits covering Spikevax, mNEXSPIKE and mResvia in the US and Europe on October 28, and the cross-licenses in infectious disease carry no payment obligation either way. GSK asked a Delaware federal court on Friday to dismiss its infringement claims with prejudice, so they cannot be refiled. That removes an overhang on Moderna's COVID and RSV franchises without costing cash — a clean win for a company that already booked a $950 million litigation settlement in its year-to-date results. The remaining patent exposure is the separate Pfizer/BioNTech web of suits, including Moderna's own 2022 case against Pfizer, which this deal does not touch.
At the time of this announcement, MRNA was trading at $258.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.2B. The 52-week trading range was $22.28 to $267.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.